Cost-effectiveness of diagnostic imaging work-up and treatment for patients with intermittent claudication in The Netherlands  by Visser, K. et al.
Cost-effectiveness of Diagnostic Imaging Work-up and Treatment for
Patients with Intermittent Claudication in The Netherlands
K. Visser1,2, S. O. de Vries3, P. J. E. H. M. Kitslaar4, J. M. A. van Engelshoven5
and M. G. M. Hunink1,2,6
From the Program for the Assessment of Radiological Technology (ART Program), Departments of 1Epidemiology &
Biostatistics and 2Radiology, Erasmus MC, Rotterdam, 3Department of Psychiatry, University Hospital Groningen,
Departments of 4Surgery and 5Radiology, University Hospital Maastricht, The Netherlands and 6Department of
Health Policy and Management, Harvard School of Public Health, Boston, MA, U.S.A.
Objective: to determine the societal cost-effectiveness of various management strategies, including both the diagnostic
imaging work-up and treatment, for patients with intermittent claudication in The Netherlands.
Methods: a decision-analytic model was used and included probability and quality of life data available from the literature.
A cost-analysis was performed in a university setting in The Netherlands. Imaging work-up options included magnetic
resonance angiography (MRA), color-guided duplex ultrasound, or intraarterial digital subtraction angiography (DSA)
and treatment options were percutaneous transluminal angioplasty with selective stent placement if feasible or bypass
surgery. Management strategies were defined as combinations of imaging work-up and treatment options. A conservative
strategy with no imaging work-up and walking exercises was considered as reference. Main outcome measures were quality-
adjusted life years (QALYs), lifetime costs (d), and incremental cost-effectiveness (CE) ratios. The base-case analysis
evaluated 60-year-old men with severe unilateral intermittent claudication of at least one year duration.
Results: the range in QALYs and costs across management strategies that considered angioplasty as only treatment option
was small (maximum difference: 0.0033 QALYs and d451). Similarly, the range was small across management strategies
that considered angioplasty if feasible otherwise bypass surgery (maximum difference: 0.0033 QALYs and d280). MRA in
combination with angioplasty (6.1487 QALYs and d8556) had a CE ratio of d20 000/QALY relative to the conservative
strategy. The most effective strategy was DSA in combination with angioplasty if feasible otherwise bypass surgery (6.2254
QALYs and d18 583) which had a CE ratio of d131 000/QALY relative to MRA in combination with angioplasty.
Conclusion: the results suggest that the imaging work-up with non-invasive imaging modalities can replace DSA for the
work-up of patients with intermittent claudication without a substantial loss in effectiveness and a minimal cost-reduction.
Management strategies including angioplasty are cost-effective in the Netherlands but although strategies including bypass
surgery are more effective, their incremental costs are very high.
Key Words: Cost-effectiveness; Intermittent claudication; Magnetic resonance angiography; Duplex ultrasound; Digital
subtraction angiography; Percutaneous transluminal angioplasty; Bypass surgery.
Introduction
Peripheral arterial disease (PAD) presenting as inter-
mittent claudication is common among the elderly
with a prevalence ranging from 0.6 to 7.0% and
increasing with age.1 The diagnosis of PAD is
established based on the history, physical examina-
tion, and a decreased ankle-brachial pressure index.
If a vascular intervention is considered, diagnostic
imaging work-up is necessary. The current work-up
may include intraarterial digital subtraction angiog-
raphy (DSA), magnetic resonance angiography
(MRA), and color-guided duplex ultrasound (DUS).
DSA is considered to be the reference (`` gold'') stand-
ard but involves small risks,2,3 has contra-indications
such as contrast media reactions and renal impair-
ment, and is expensive compared with non-invasive
tests. MRA is nearly as accurate as DSA but has
contra-indications such as claustrophobia and the
presence of a pacemaker whereas color-guided DUS
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has reasonable diagnostic accuracy and low costs but
is operator-dependent.4
Treatment options for PAD include percutaneous
transluminal angioplasty with selective stent place-
ment, bypass surgery, or a more conservative
approach with walking exercises. Angioplasty is a
minimally invasive procedure and, compared with
bypass surgery, both the complication risks and costs
are lower but the rate of failure due to restenosis or
occlusion is somewhat higher.5±8 Walking exercise is
regarded as an effective method for improving symp-
toms of claudication but not all patients benefit,
and the costs are not as low as expected if patient
time spent on walking is considered in terms of its
monetary value.9±12
For the diagnostic imaging work-up and for the
treatment of patients with intermittent claudication
cost-effectiveness analyses have been performed for
the United States.13,14 It is, however, unclear to what
extent cost-analyses, and thereby cost-effectiveness
analyses, are generalizable across countries since dif-
ferences exist in the finance systems and regulations
of health care systems. In particular, it is unclear if the
published cost-effectiveness analyses of the diagnostic
work-up and treatment for patients with intermittent
claudication can be applied to the situation in The
Netherlands. The main purpose of our study was to
evaluate the cost-effectiveness of management strate-
gies, including the imaging work-up and treatment,
for patients with intermittent claudication in The
Netherlands. A second purpose was to study if the
results from the previous cost-effectiveness analyses
performed in the United States were generalizable to
The Netherlands.
Methods
Decision models
For the current study we used a previously developed
decision-analytic model evaluating the (societal) cost-
effectiveness of diagnostic imaging strategies14 and
treatment strategies.13 The model consisted of a
Markov Monte Carlo model that was embedded in
a larger decision-analytic model. The current study is
a simulation study in which hypothetical patients
were followed lifelong from the time that the initial
diagnostic work-up was performed. We considered
previously untreated patients presenting with severe
unilateral claudication of at least one year duration
who had at least one significant lesion (450% arterial
diameter reduction) that was located predominantly
suprainguinal or infrainguinal.
Diagnostic work-up
The pre-treatment imaging work-up of patients with
intermittent claudication consisted of localization of
the lesion (predominantly suprainguinal or infraingu-
inal) and determining a treatment plan (angioplasty,
bypass surgery, or walking exercise). The following
imaging modalities for the pre-treatment work-up
were evaluated: gadolinium-enhanced MRA, color-
guided DUS, and intraarterial DSA. DSA was the ref-
erence standard in our analysis and we assumed that
MRA and color-guided DUS could result in equivocal
test results or could induce false test results. Equi-
vocal test results were defined as a technical failure
of the test, no treatment plan could be made on the
basis of the test result, or the test could not be per-
formed because of a contra-indication. A DSA was
always performed for equivocal results and in the
event that no lesion was localized.
False test results could lead to inappropriate treat-
ment of patients. We assumed that if an angioplasty
was incorrectly recommended to a patient that the
diagnostic DSA performed as part of the angioplasty
procedure would detect the false test result. If the
angioplasty procedure had to be stopped the costs of
the procedure equaled the costs of a diagnostic DSA
plus some extra costs for inefficient use of personnel,
equipment, and housing. An incorrectly recom-
mended bypass surgery was not detected unless
patients returned to the hospital with persistent symp-
toms of intermittent claudication after treatment of the
incorrect location, at which time we assumed they
would be re-evaluated with a DSA.
Treatment and follow-up
Treatment options for patients with intermittent clau-
dication were supervised exercise (EX), percutaneous
transluminal angioplasty with selective stent place-
ment (PTA), or bypass surgery (BS). Of all patients,
we assumed that 95% had lesions suitable for invasive
treatment (angioplasty with selective stent placement
or bypass surgery)15 and the remainder of the patients
entered a supervised exercise program. Feasibility of
percutaneous treatment for suprainguinal or infraigu-
inal lesions was determined according to published
guidelines.16 Bypass surgery was considered if angio-
plasty was not feasible depending on the management
strategy considered. A failure of invasive treatment
was defined as a graft failure or restenosis in com-
bination with severe claudication or progression to
critical limb ischemia (defined as rest pain, ulcers or
gangrene). A failure of supervised exercise was
214 K. Visser et al.
Eur J Vasc Endovasc Surg Vol 25, March 2003
defined as development of critical limb ischemia.
Patients that developed critical limb ischemia were
always treated invasively. Patients with failures
underwent a DSA to determine appropriate treatment.
In clinical practice invasive treatment for recurrent
symptoms is not utilized in an unlimited fashion and
we therefore limited the maximum number of inter-
ventions per limb to three. If the maximum number of
interventions per limb was reached and the patient
had critical limb ischemia then the affected limb was
amputated.
The embedded model that evaluated treatment was
a Markov decision model in which the patient's life-
span was modeled from the time of presentation with
severe claudication until death, including treatment
and follow-up. The following health states were
considered: (1) asymptomatic or mild claudication;
(2) severe claudication; (3) critical limb ischemia; and
(4) amputation of the limb. Patients with severe inter-
mittent claudication were distinguished from patients
with no or mild claudication by a threshold maximum
walking distance of less than 250 m, which was used
in a previous analysis.13 Maximum walking distance
was defined as the distance at which the patient was
forced to stop because of severe symptoms of inter-
mittent claudication. To determine the maximum
walking distance patients were asked to walk back
and forth between two fixed points in the hospital
corridors at a predetermined speed. Speed was held
constant by monitoring the time needed to cover the
distance (25 m) between these two points. The avail-
able data did not permit making a distinction between
asymptomatic patients and patients with mild claudi-
cation. Implicitly, it was assumed that severe symp-
toms of intermittent claudication justified the use of
invasive treatment. Patients could develop recurrent
or contralateral symptoms during follow-up which
would then be evaluated with a DSA and, depending
on the management strategy, treated with angioplasty
or bypass surgery.
Management strategies
The following management strategies were con-
sidered: (1) MRA in all patients and subsequent
angioplasty for patients with suitable lesions other-
wise patients entered a supervised exercise program
[`` MRAPTA/EX'']; (2) MRA in all patients and sub-
sequent angioplasty for patients with suitable lesions
and bypass surgery for the remainder of patients
[`` MRAPTA/BS/EX'']; (3) color-guided DUS in all
patients and subsequent angioplasty for patients
with suitable lesions otherwise patients entered
a supervised exercise program [`` DUSPTA/EX''];
(4) color-guided DUS in all patients and subsequent
angioplasty for patients with suitable lesions and
bypass surgery for the remainder of patients
[`` DUSPTA/BS/EX'']; (5) DSA in all patients and
subsequent angioplasty for patients with suitable
lesions otherwise patients entered a supervised exer-
cise program [`` DSAPTA/EX'']; (6) DSA in all
patients and subsequent angioplasty for patients
with suitable lesions and bypass surgery for the
remainder of patients [`` DSAPTA/BS/EX'']; (7) a
conservative strategy as the reference strategy in
which all patients entered a supervised exercise pro-
gram [`` NotestEX''] and only evaluated further if
critical limb ischemia developed. Strategies that
started with supervised exercise for all patients and
used imaging work-up with subsequent invasive
treatment for patients who failed to respond to con-
servative treatment were not considered in the analy-
sis since a previous analysis showed that there was
virtually no difference in outcome compared with
strategies that started with imaging work-up and
invasive treatment.13
Data sources
Costs
The cost calculations were performed according to the
Dutch guidelines for cost calculations in health care17
and all costs relevant to society were considered.
Direct medical costs included costs for personnel,
materials, equipment, housing, hospital admission,
and overhead. The costs for equipment were calcu-
lated by using the annuitization method with a 3%
discount.18 It was assumed that equipment had a life-
time of ten years and the yearly costs of maintenance
of the equipment were 10%. Overhead was estimated
at 15% of the costs for personnel, materials, and equip-
ment. As direct non-medical costs we considered
travel expenses and patient time. Patient time spent
on interventions was included as a monetary cost by
using the average gross earnings per year for men
aged between 55 and 65 in The Netherlands (d32 000;
1997). The cost for radiological interventions were
available from the Department of Radiology (1997)
and the costs for surgical interventions were available
from the Department of Surgery (1993), both from
the University Hospital Maastricht. Costs of an one-
day-admission (d167) were assumed to be half of an
overnight admission (d333).17 Costs for complications
of invasive treatments and costs for follow-up after
amputation of the limb were based on literature
data.19,20 All costs were updated with the consumer
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price index to 1999 costs and converted to Euros (d)
(2.20 Dutch Guildersd11.06 US dollars, 1999
Dutch Bureau of Statistics) (Table 1).
Down-stream induced medical costs were not
considered since the treatment of peripheral arterial
disease does not prolong life but improves the quality
of life of the patient. Also, friction costs (costs for
productivity losses calculated as the costs of replace-
ment of an employee) were not considered since most
patients with peripheral arterial disease are retired.
Diagnostic work-up
Intraarterial DSA had a small risk of mortality and
morbidity (Table 2).2,3,21 For gadolinium-enhanced
MRA and color-guided DUS no major complications
or mortality were reported in the literature and, there-
fore, we assumed that non-invasive tests did not
involve any risks. Sensitivities for MRA and color-
guided DUS to detect a stenosis of more than 50%
were available from a meta-analysis (Table 2).4 Also
the test characteristics of MRA and color-guided DUS
to assess the treatment option (angioplasty vs bypass
surgery vs lesions not suitable for invasive treatment)
were available from the literature.15,22±24 Data on
equivocal MRA and color-guided DUS results were
available from the literature.4,15,22,24,25
Exercise program
Estimates for the supervised exercise program were
available from a study performed at the University
Table 1. Costs of interventions in 1999 Euros (d).
Variable Baseline value
(alternative values)
Source United States
costs (1998 $) xx
Interventions
MRA 494 UHM 574
Color-guided DUS 184 UHM 243
Intraarterial DSA 1062 (605)  UHM 1822 (1183) k k
Planned angioplasty and stopped after angiography y 357 UHM 316
Angioplasty for suprainguinal lesions 1934 UHM 8290
Angioplasty for infrainguinal lesions 1655 UHM 4580
Bypass surgery for suprainguinal lesions 10 179 UHM 25 788
Bypass surgery for infrainguinal lesions 5452 UHM 18 108
Amputation above the knee 9817 UHM 15 830
Amputation below the knee 9379 UHM 8550
Supervised exercise program, time costs per year 1267 13,28 4147
Complications
DSA z 666 Assumption 7393
Systemic complications x 6894 19 10 723
Mortality from vascular interventions k 2286 Assumption 12 758
Follow-up
Long-term systemic complications{ 1781 19 11 832
Follow-up visit including office visit,
color-guided DUS and ABI measurement
298 UHM 392
Follow-up after amputation of the limb
First year  45 225 20 zz ±{{
Subsequent years yy 11 079 20 zz ±{{
UHMUniversity Hospital MaastrichtThe costs for hospitalization due to DSA were estimated based on the duration of hospitalization for 11 diagnostic DSAs performed in the
University Hospital Maastricht between May 1999 and November 2000 (2 patients returned home after 6±8 h of bedrest and observation,
2 patients were admitted for one night, and 7 patients were admitted for two nights). The value between brackets represents the costs for a
DSA with a short period of bedrest and observation after which the patient can return home. This value was used in the sensitivity analyses.
yExtra costs compared with a DSA for a planned but not performed angioplasty.
zFor complications of DSA it was assumed that the hospital admission was prolonged with two days.
xCosts equaled the costs of treatment for myocardial infarction, which was used as a proxy for complications induced by vascular
procedures.
{Costs of survivors of myocardial infarction were used as a proxy for the costs of long-term systemic complications.
kCosts of dying from vascular procedures were assumed to equal the costs of two days of admission at an intensive care unit.Costs included rehabilitation, prosthesis, costs for time spent on rehabilitation, adjustments to the house, domiciliary care, and admission
to a nursing home due to amputation of the limb, if necessary.
yyCosts included maintenance of prosthesis, domiciliary care, and admission to nursing home due to amputation of the limb, if necessary.
zz In the study by Pernot et al.20 87 amputees were followed and data on their healthcare utilization was collected. With use of the Dutch
guidelines for costs calculations, costs were allocated to the utilized care.
xxUnited States costs were presented in 1998 US $. Updating the costs to 1999 d would slightly increase the presented figures.
{{Costs for follow-up after amputation of the limb were not available for first year vs subsequent years.
k kThe number between brackets represents the costs of an outpatient DSA.
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Hospital Groningen, The Netherlands.26 In that study
patients followed a supervised exercise program in
which they were asked to walk a certain fixed distance
each day and instructed to pause when symptoms of
claudication appeared. During the first six months of
the exercise program patients had four hospital visits.
Invasive treatment and follow-up
Invasive treatment of suprainguinal disease consisted
of angioplasty with selective stent placement and
aortic bifurcation surgery. Invasive treatment of infra-
inguinal disease consisted of angioplasty, femoro-
popliteal bypass surgery, and femoro-infrapopliteal
bypass surgery. The invasive treatment options
together represent approximately 85% of all inter-
ventions performed for PAD in the Brigham and
Women's between 1990 and 1995. We used the distri-
bution of treatment options of the United States for
The Netherlands since the most often performed
procedures in the United States are the same as in The
Netherlands.27 Most lesions being treated invasively
for the first time were located suprainguinally and
more suprainguinal lesions were suitable for angio-
plasty than infrainguinal lesions.13,28 Risk of mortality
and systemic complications for vascular interventions
were available from the literature.5,6,29±31 For patency
estimates we used published meta-analyses5±7 and in
the model a time-dependent graft failure rate was
used. Two-year patency estimates are shown as an
illustration in Table 3. During follow-up patients
could develop critical limb ischemia and/or symp-
toms in the contralateral limb for which incidence
data were available from the literature.13,32±36 Also
age and gender adjusted estimates for the natural
mortality rate and the excess mortality due to PAD
were incorporated in the model.33,34,37±39
Health-related quality of life
The life expectancy of patients was adjusted with the
quality of life. Mostly, health-related quality of life is
Table 2. Test characteristics of imaging modalities.
Variable Base-case (range or
alternative value) 
Source
MRA
Sensitivity (stenosis 50%) 0.98 (0.96±0.99) 4
Additional work-up with DSA for equivocal MRA results 0.09 (0.06±0.14) 4, 15, 22
Probability that MRA result suggests angioplasty given that lesion is
suitable for angioplasty
0.79 (0.87) 22, 15
Probability that MRA result suggests angioplasty given that lesion is
suitable for bypass surgery
0.03 (0.065) 22, 15
Probability that MRA result suggests angioplasty given that lesion is
not suitable for invasive treatment
0 (0.065) 22, 15
Probability that MRA result suggests bypass surgery given that
lesion is suitable for bypass surgery
0.97 (0.87) 22, 15
Probability that MRA result suggests bypass surgery given that
lesion is suitable for angioplasty
0.14 (0.65) 22, 15
Probability that MRA result suggests bypass surgery given that
lesion is not suitable for invasive treatment
0 (0.065) 22, 15
Color-guided DUS
Sensitivity (stenosis 50%) 0.88 (0.84±0.91) 4
Additional work-up with DSA for equivocal color-guided DUS
results
0.23 (0.08±0.37) 4, 24, 25
Probability that color-guided DUS result suggests angioplasty given
that lesion is suitable for angioplasty
0.60 (0.93) 23, 24
Probability that color-guided DUS result suggests angioplasty given
that lesion is suitable for bypass surgery
0.08 (0.10) 23, 24
Probability that color-guided DUS result suggests angioplasty given
that lesion is not suitable for invasive treatment
0.09 (0.24) 23, 24
Probability that color-guided DUS result suggests bypass surgery
given that lesion is suitable for bypass surgery
0.87 (0.90) 23, 24
Probability that color-guided DUS result suggests bypass surgery
giiven that lesion is suitable for angioplasty
0.36 (0.07) 23, 24
Probability that color-guided DUS result suggests bypass surgery
given that lesion is not suitable for invasive treatment
0.09 (0.29) 23, 24
DSA
Major complications 0.03 (0.02±0.05) 2
Mortality 3.3  10ÿ4 (2.9±16.2  10ÿ4) 3, 21
Presented values are probabilities.
Cost-effectiveness of Imaging Work-up and Treatment for Claudication 217
Eur J Vasc Endovasc Surg Vol 25, March 2003
measured on a scale from 0 (death) to 1 (perfect
health). For intermittent claudication the health values
were available from patients that participated in
the supervised exercise program and the obtained
responses to the EuroQol were transformed to time
tradeoff values.40 For patients with critical limb ische-
mia or an amputation time tradeoff values were used
from the literature.41 Health values for systemic com-
plications and angina pectoris were incorporated by
using a simple multiplicative relation.42 Actual values
are presented in Table 4.
Table 3. Treatment and follow-up.
Variable Base-case (range or alternative value)  Source
Natural mortality
Excess mortality for PAD (incidence rate ratio) 3.14 (2.74±3.54) 33, 35, 37±39
Mortality from vascular interventions, high risk/low risk y
Aortic bifurcation grafts 0.044 (0.032±0.055)/0.007 (0.005±0.009) 6
Suprainguinal angioplasty with selective stent placement 0.013 (0±0.037)/0.001 (0±0.029) 5
Infrainguinal bypass surgery 0.047 (0.008±0.127)/0.008 (0.001±0.022) 29
Infrainguinal angioplasty 0.025 (0±0.264)/0.002 (0±0.021) 29
Amputation, Age5 75/Age 75 0.098 (0.077±0.119)/0.147 (0.113±0.181) 30
Systemic complications
Aortic bifurcation grafts 0.083 (0.063±0.102) 6
Suprainguinal angioplasty with selective stent placement 0.013 (0±0.035) 5
Infrainguinal bypass surgery 0.085 (0.027±0.13) 29
Infrainguinal angioplasty 0.013 (0.002±0.110) 29
Amputation 0.38 (0.377±0.383) 31
Two-year patency in patients with intermittent claudication
Aortic bifurcation grafts 0.95 6
Suprainguinal angioplasty with selective stent placement,
stenosis/occlusion
0.84/0.67 5
Infrainguinal bypass surgery, autologous vein/PFTE, above-knee
anastomosis/PFTE below-knee anastomosis
0.89/0.86/0.80 7
Infrainguinal angioplasty, stenosis/occlusion 0.75/0.46 7
Probability of suprainguinal disease
First intervention 0.56 (0.12±0.85) 13
For subsequent interventions with previously suprainguinal disease 0.31 (0.13±0.49) 13
For subsequent interventions with previously infrainguinal disease 0.17 (0.09±0.25) 13
Suitability for angioplasty, claudication
Suprainguinal disease, first intervention 0.51 (0.74) 13, 28
Suprainguinal disease, subsequent interventions 0.33 (0.74) 13, 28
Infrainguinal disease, first intervention 0.18 (0.50) 13, 28
Infrainguinal disease, subsequent interventions 0.23 (0.50) 13, 28
Critical limb ischemia
Annual incidence rate, Age5 65/Age 65 0.017 (0±0.039)/0.036 (0±0.075) 33±36
Five-week probability following graft failure: pre-treatment symptoms,
claudication/critical limb ischemia
0.062 (0±0.014)/0.242 (0.14±0.36) 13
Amputation
Proportion of above knee amputations 0.08 (0.03±0.13) 13
Annual incidence rate of progression below-knee to above-knee amputation 0.015 (0±0.07) 13
Severe vs mild intermittent claudication
Relative risk of severe intermittent claudication after stopping exercise 5.81 (1.8±18.5) 13
Relative risk of severe intermittent claudication after graft failure 1.36 (0.96±1.92 13
Contralateral symptoms
Mean annual rate 0.149 32
ePTFE: expanded polytetrafluoroethylene.Presented values are probabilities unless stated otherwise.
yPatients that are aged over 65 years with critical limb ischemia and patients with history of coronary artery disease have a higher risk of
mortality from vascular interventions.
Table 4. Health-related quality of life values.
Variable Base-case (range) Source
Asymptomatic or mild intermittent
claudication
0.79 (0.75±0.83) 40
Severe intermittent claudication 0.71 (0.67±0.75) 40
Critical limb ischemia 0.35 (0.15±0.55) 41
Above knee amputation 0.20 (0.00±0.40) 41
Below knee amputation 0.61 (0.41±0.81) 41
Systemic complications 0.72 (0.60±0.90) 42
Angina pectoris 0.90 (0.60±1.00) 42
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Cost-effectiveness analysis
Our primary outcome measures were quality-adjusted
life years (QALYs) and lifetime costs (both discounted
at 3%)43 and management strategies were ordered by
increasing QALYs. QALYs are a measure of the health
outcome: to each period of time a weight ranging
from 0 (health state equivalent to death) to 1 (optimal
health) corresponding to the health-related quality of
life during that period was assigned. These are then
aggregated across time periods. Cost-effectiveness
was determined by excluding (extended) dominated
strategies and then calculating the incremental cost-
effectiveness (CE) ratio. A strategy was considered to
be dominated by another strategy if the latter yielded
higher QALYs at a lower cost and a strategy was
considered to be extended dominated by another
strategy if the latter yielded higher QALYs and had a
lower incremental CE ratio. The incremental CE ratio
of a strategy was calculated as the difference in costs
divided by the difference in QALYs compared with
the next best strategy and represents the additional
costs in Euros per additional QALY gained for a strat-
egy compared with the next best strategy.
The baseline analysis evaluated a cohort of 60-year-
old men that presented with unilateral severe symp-
toms of intermittent claudition of at least one year
duration, an ankle brachial index pressure of 0.70,
and no history of coronary artery disease. We also
considered 40-year-old men (all other characteristics
similar to the base-case) and 70-year-old men with a
history of coronary artery disease (all other character-
istics similar to the base-case). Bypass surgery was not
performed in patients with a history of coronary
artery disease because of high complication rates
unless critical limb ischemia developed.
The Markov Monte Carlo model embedded in the
larger model was modeled in a C based program-
ming language. The complete model was modeled
and analyzed in DATATM (Decision Analysis by
TreeAge, version 3.5.7, Treeage Software Inc.,
Williamstown, MA, U.S.A.). Sensitivity analyses were
performed for diagnostic work-up parameters and
also for the most influential parameters of treatment
and follow-up based on a previous analysis.13
Results
Base-case analysis
For the base-case (60-year-old male patients with
severe unilateral claudication for one year and with-
out a history of coronary artery disease) the conserva-
tive strategy (`` NotestEX'') was the least effective
and least costly (6.0606 QALYs and d6793). The
strategy `` MRAPTA/EX'' was more effective and
more costly (6.1487 QALYs and d8566) and had an
incremental CE ratio of (rounded off) d20 000/QALY
compared with the conservative strategy. The strategy
`` DSAPTA/BS/EX'' was the most effective strategy
but was also expensive (6.2254 QALYs and d18 583)
and had an incremental CE ratio of d131 000/QALY
compared with `` MRAPTA/EX''. All other manage-
ment strategies were inferior by (extended) domin-
ance meaning that another strategy was more
effective against lower costs (or with a lower incre-
mental cost-effectiveness ratio) (Table 5). Figure 1
shows that the range in costs and effectiveness across
management strategies that considered angioplasty as
the only invasive treatment option was small. The
same applied but to a lesser degree to strategies that
considered both angioplasty and bypass surgery as
treatment options.
Alternative patient cohorts
For 40-year-old male patients the incremental CE
ratios of `` MRAPTA/EX'' and `` DSAPTA/
BS/EX'' decreased (d13 000/QALY and d98 000/
QALY, respectively). For 70-year-old male patients
with a history of coronary artery disease only man-
agement strategies with angioplasty as treatment
option were considered and it was found that
Table 5. QALYs, costs, and incremental CE ratios of management
strategies for patients with intermittent claudication.
Management strategies QALYs  Cost (d) Increm CE ratio
(d/QALY) x
NotestEX 6.0606 6793 ±
DUSPTA/EX y 6.1465 8546 ED
MRAPTA/EX y 6.1487 8566 20, 138
DSAPTA/EX y 6.1498 8997 ED
DUSPTA/BS/EX z 6.2002 18 720 D
MRAPTA/BS/EX z 6.2136 18 440 ED
DSAPTA/BS/EX z 6.2254 18 583 130 557
QALYsQuality adjusted life years; Increm. CE ratio incremental
cost-effectiveness ratio; DUS color-guided duplex ultrasound;
MRAmagnetic resonance angiography; DSAdigital subtraction
angiography; EX supervised exercise program; PTApercuta-
neous transluminal angioplasty with selective stent placement;
BSbypass surgery; Ddominated; ED extended dominated. Strategies were ordered by increasing effectiveness.
yPatients with lesions suitable for angioplasty underwent angio-
plasty otherwise patients entered a supervised exercise program.
zPatients with lesions suitable for angioplasty underwent angio-
plasty otherwise patients underwent bypass surgery. Patients with
lesions not suitable for invasive treatment entered a supervised
exercise program.
xNumbers could differ slightly from calculations based on figures
available in the table because of rounding.
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`` DUSPTA/EX'' had an incremental CE ratio of
d48 000/QALY compared with the conservative
management strategy and `` MRAPTA/EX'' had an
incremental CE ratio of d75 000/QALY compared
with `` DUSPTA/EX''.
Sensitivity analysis
The results were sensitive for the costs of MRA. Com-
pared with the conservative strategy the incremental
CE ratio of `` MRAPTA/EX'' increased from
d20 000/QALY (base-case) to d31 000/QALY with an
increase of the costs of MRA to d544 and to d115 000/
QALY if the costs of MRA were assumed to be 150%
that of baseline (d741). The results were not sensitive
for lower costs of MRA: the incremental CE ratio
decreased to d17 000/QALY if MRA cost d247. Using
alternative estimates for the treatment recommenda-
tions made by color-guided DUS (Table 2), `` MRA
PTA/EX'' was dominated and `` DUSPTA/EX'' had
an incremental CE ratio of d20 000/QALY.
Criteria for the suitability of lesions for percutan-
eous interventions vary across centers. In a sensitivity
analysis we assumed that more patients with intermit-
tent claudication had lesions suitable for angioplasty
(0.74 for suprainguinal lesions and 0.50 for infraingu-
inal lesions, Table 3). For all strategies the effectiveness
increased (range of the gain: 0.0603 to 0.0951 QALYs)
whereas the costs increased for management
strategies with angioplasty as the only invasive treat-
ment option (range of increase: d1197 to d1243) but
decreased for management strategies with both angio-
plasty and bypass surgery (range of decrease: d1739
to d2072). The incremental CE ratios of `` MRA
PTA/EX'' and `` DSAPTA/BS/EX'' decreased slightly
to d17 000/QALY and d110 000/QALY, respectively.
Performing an angioplasty in conjunction with a
diagnostic DSA did not change the incremental CE
ratios of the base-case analysis but the effectiveness
increased with 0.007 QALYs and the cost decreased
with d91 for strategies with DSA as first imaging
modality (`` DSAPTA/EX'' and `` DSAPTA/
BS/EX'', respectively). On the other hand, the incre-
mental CE ratios and order of strategies changed if all
patients could return home after a short period of
observation and bedrest after a DSA (cost for a DSA
decrease to d605, Table 1). In this case the incremental
CE ratios were d17 000/QALY for `` DUSPTA/EX''
compared with the conservative strategy, d47 000/
QALY for `` DSAPTA/EX'' compared with `` DUS
PTA/EX'', and d126 000/QALY for `` DSAPTA/
BS/EX'' compared with `` DSAPTA/EX''.
Discussion
The current study evaluated different management
strategies for patients with intermittent claudication.
We found that management strategies that limited
invasive treatment to angioplasty were all similar in
costs and effectiveness irrespective of the imaging
modality performed. Management strategies that
also included bypass surgery had a clearly higher
cost than strategies that limited treatment to angio-
plasty and there was a marginal gain in effectiveness.
DSA with angioplasty and bypass surgery was the
most effective management strategy but the differ-
ences with the strategies that started with MRA or
color-guided DUS was small. Apparently, the
diagnostic work-up had minor influence on the cost-
effectiveness using the assumptions and management
strategies as described.
At first glance, the differences in costs, risks, and
diagnostic accuracy between the considered imaging
modalities seem large but if all relevant lifetime effects
and costs are taken into account then these differences
become almost negligible. Treatment of PAD improves
the patients' quality of life by treating the symptoms
and does not prolong life expectancy of patients with
intermittent claudication. Therefore, only a small gain
in quality-adjusted life years (QALYs) will be found.
Furthermore, a small cost-reduction could be achieved
if no overnight admissions are necessary after a DSA
and all patients could return home after a period of
observation and bedrest. The choice between one-day
admissions and overnight admissions are mainly
determined by hospital policies but also by individual
Fig. 1. Quality adjusted life years (QALYs) vs lifetime costs for the
base-case analysis.
220 K. Visser et al.
Eur J Vasc Endovasc Surg Vol 25, March 2003
patient characteristics and the condition of the patient
after the DSA. Finally, if the flexibility of the interven-
tional team and the workflow allow for planning of a
diagnostic DSA in conjunction with an angioplasty
without knowing if lesions are suitable for angioplasty
then the effectiveness will increase and the costs
will decrease. These latter effectiveness gains and
cost-savings are, however, so minimal that one should
carefully weigh their advantage against making
changes in the work process.
A limitation of our analysis was that we assumed
that DSA would be performed for recurrent or con-
tralateral symptoms instead of MRA or color-guided
DUS. We made that assumption because non-invasive
imaging modalities were not as often used during
the mid-90's (i.e., the time the decision models were
developed) as nowadays. However, the results would
only change minimally and probably not change the
conclusions if we were to assume that non-invasive
modalities would have been performed in case of
recurrent or contralateral symptoms. This is because,
first, in the current analysis we compared alternative
management strategies for patients with intermittent
claudication and the main outcome measure is the
difference in costs and effects between the alternative
strategies. In all alternative strategies DSA would
be performed for symptoms during follow-up and
the differences in the proportion of patients whom
would undergo DSA during follow-up across the
alternative strategies is minimal and would thereby
not affect the differences between strategies. Second,
replacing DSA with non-invasive modalities would
give a cost-reduction and avoids the risk of an inva-
sive modality but this should be weighed against the
consequences of false test results induced by non-
invasive tests. Third, although MRA and color-guided
DUS are often indicated as initial imaging work-up
there will always be some patients in whom DSA
would be preferred. Proceeding to DSA immediately
is particularly efficient if it is likely that percutaneous
treatment can be performed in conjunction with the
DSA or if the patient has critical limb ischemia. Both
situations are more likely in patients with recurrent
symptoms. In summary, although our assumption is
not completely valid for today's clinical practice, we
believe that it did not have a major impact on the
results and conclusions of the presented study.
Other limitations of our study were limitations that
are inherent to decision models and cost-effectiveness
analyses. Several secondary data-sources available
from the literature were used as input data for
the parameters in the decision-analytic model. For
instance, different data-sets were used to model
changes in the severity of claudication. Where
possible we adjusted the data for important potential
confounders. In addition, assumptions had to be
made to keep the problem manageable. Health states
for intermittent claudication, for example, were
divided into mild vs severe claudication by an arbi-
trary cutoff in maximum walking distance and this
subdivision did not take into account a patient's life-
style and occupation. Furthermore, it was assumed
that DSA was the reference standard in the diagnostic
work-up for PAD which is often done4 but can be
questioned since some studies reported that MRA
yielded better results in the detection of patent runoff
vessels than DSA.44,45 Lastly, we did not consider
medical therapy and smoking cessation as separate
treatment options but rather considered these as a
part of the general management of all patients with
intermittent claudication independent of the imaging
and revascularization strategy considered.
The Dutch costs for vascular interventions were
lower than the United States costs but not all costs
decreased by the same ratio (Table 1). A previous
cost-effectiveness analysis focusing on the same clin-
ical problem as in this study using United States costs
showed that the differences between imaging strate-
gies were small.14 The incremental CE ratio for MRA
with angioplasty as the only invasive treatment option
compared with the conservative strategy was $35 000/
QALY (US costs, 1998) whereas the CE ratio for DSA
with both angioplasty and bypass surgery relative to
MRA with angioplasty as treatment option was
$345 000/QALY (US costs, 1998). Therefore, the incre-
mental CE ratios for the United States were higher
than the CE ratios for The Netherlands and adjust-
ments for inflation and currency (d1 $1.06, 1999)
would make the differences even larger.
The current analysis showed that cost-effectiveness
analyses across countries do not necessarily yield the
same results. The order of the optimal strategies was
the same but the magnitude of the incremental CE
ratios differed between the United States and The
Netherlands. The generally reported range of CE
ratios for the United States varies between $10 000
and $100 000/QALY.46 Applying this range to the pre-
viously published cost-effectiveness analysis based on
US cost data we would conclude that management
strategies that limit invasive treatment to angioplasty
for claudication are cost-effective but that bypass
surgery for claudication is not warranted. For The
Netherlands the approximate threshold incremental
CE ratio can be deduced from the fact that heart trans-
plantation at a cost of d33 000/QALY (72 000 Dutch
guilders per QALY)47 is considered acceptable whereas
lung transplantation48 at a cost of d54 000/QALY
(118 000 Dutch guilders per QALY) is considered too
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high in comparison to the effectiveness to justify
widespread implementation. Applying a threshold
incremental CE ratio of between d33 000/QALY and
d54 000/QALY, the same conclusion concerning
management strategies for patients with intermittent
claudication in The Netherlands would be drawn as in
the United States. Therefore, although the incremental
CE ratios for the United States were higher than for
The Netherlands, the practical implication for this
particular clinical problem is the same. One marginal
note on the comparison of CE ratios between countries
is that we assumed that effectiveness was equal across
countries. As long as the demographic and epidemio-
logic factors are comparable this seems a reasonable
assumption since biological variation between people
is small.
In conclusion, the results suggest that for patients
with severe unilateral intermittent claudication of at
least one year duration non-invasive imaging modal-
ities can replace DSA without an important loss in
effectiveness and a minimal cost-reduction. In add-
ition, compared with angioplasty, the additional gain
in effectiveness with bypass surgery does not justify
the additional expense. Furthermore, although abso-
lute incremental CE ratios were different between
The Netherlands and United States, the implications
for both countries are the same.
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